NCT02022657View on ClinicalTrials.gov

Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2017

Conditions
PrEP Adherence Monitoring
Interventions
DRUG

Truvada

Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP

Trial Locations (2)

80045

University of Colorado Denver, Aurora

94102

University of California San Francisco/San Francisco Department of Public Health, San Francisco

All Listed Sponsors
collaborator

San Francisco Department of Public Health

OTHER_GOV

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Colorado, Denver

OTHER

NCT02022657 - Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots | Biotech Hunter | Biotech Hunter